Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy

Apellis Pharmaceuticals has just announced that they have received Orphan Drug Designation from the FDA for APL-2, a C3 complement inhibitor. The company is currently investigating the drug as a…

Continue Reading Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy

Making Strides Towards New Treatment Options for Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis (NASH), is condition most commonly caused by obesity or type 2 diabetes. It can result in fibrosis, complications in the lung and cardiac system, liver cancer, liver cirrhosis,…

Continue Reading Making Strides Towards New Treatment Options for Nonalcoholic Steatohepatitis

Poll Finds Broad Support For The Use of Gene Editing to Protect Against Genetic Diseases

According to a story from ksl.com, a recent poll found that the majority of Americans are in support of using gene editing technology in order to protect newborns from genetic…

Continue Reading Poll Finds Broad Support For The Use of Gene Editing to Protect Against Genetic Diseases
Opinion: It’s Pretty Obvious That Hospitals Are Overcharging For Just About Everything
1662222 / Pixabay

Opinion: It’s Pretty Obvious That Hospitals Are Overcharging For Just About Everything

The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Patient Worthy. According to a story from Vox, a review of over…

Continue Reading Opinion: It’s Pretty Obvious That Hospitals Are Overcharging For Just About Everything

Interim Results from Phase 2a Trial for Nontuberculous Mycobacterial Lung Disease Bring Hope

Nontuberculous mycobacterial (NTM) lung infection occurs when someone inhales nontuberculous mycobacteria from the environment. There are various types of this bacteria, giving NTM different forms. But in all types of NTM,…

Continue Reading Interim Results from Phase 2a Trial for Nontuberculous Mycobacterial Lung Disease Bring Hope
ICYMI: More Steps Required for Experimental ADPKD Drug in Order to Obtain Orphan Designation
TeroVesalainen / Pixabay

ICYMI: More Steps Required for Experimental ADPKD Drug in Order to Obtain Orphan Designation

According to a story from thenewsreports.com, the biopharmaceutical company XORTX Therapeutics, Inc., recently announced that the company and its partner Cato Clinical Research have received correspondence from the US Food…

Continue Reading ICYMI: More Steps Required for Experimental ADPKD Drug in Order to Obtain Orphan Designation
ICYMI: Experimental Treatment for Duchenne Muscular Dystrophy Shows Potential in Early Trial
931527 / Pixabay

ICYMI: Experimental Treatment for Duchenne Muscular Dystrophy Shows Potential in Early Trial

According to a story from globenewswire.com, the biotechnology company Wave Life Sciences Ltd. recently announced that the tolerability and safety data from its Phase 1 clinical trial of its investigational therapy…

Continue Reading ICYMI: Experimental Treatment for Duchenne Muscular Dystrophy Shows Potential in Early Trial